Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00276601 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00276601 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
The verdict
NCT00276601, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving combination chemotherapy works in treating patients with acute promyelocytic leukemia.
Interventions
- DRUG mercaptopurine
- DRUG methotrexate
- DRUG cytarabine
- DRUG daunorubicin hydrochloride
- DRUG arsenic trioxide
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-10 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00276601
The ClinicalTrials.gov registry entry for NCT00276601 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which mercaptopurine is the first listed.
NCT00276601 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00276601 about?
NCT00276601 is a clinical study titled "Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia". RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving c...
What is the current status of trial NCT00276601?
This trial is currently completed. It is a Phase 2 study. The study started on 2004-10. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00276601?
The interventions under investigation include: mercaptopurine (DRUG), methotrexate (DRUG), cytarabine (DRUG), daunorubicin hydrochloride (DRUG), arsenic trioxide (DRUG).
Who is sponsoring clinical trial NCT00276601?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.